Table 1.
Study data set from the ten participating groups.
| Participant groupa | Sporadic cases from case–control cohorts | Sequencing method | MPM cases | Sequencing method | Familial melanoma probands | Sequencing method |
|---|---|---|---|---|---|---|
| NCI–USA | 783/11 | Panel/ES | 3 | ES | 72 | ES |
| OUH–Norway | 279 | ES | ||||
| UNIGE–Italy | 22 | Panel | 84 | Panel | 167 | Panel |
| QIMR Berghofer–Australia | 3 | ES | 206 | ES | ||
| MelaNostrum/NCI-USA | 201 | ES | ||||
| Sanger–UK | 90/25 | ES/GS | ||||
| KI–Sweden | 10 | Panel | 73 | ES | ||
| H. Bichat–France | 20/11 | ES/panel | 6/3 | ES/panel | ||
| MGH–USA | 29 | ES | ||||
| LUMC–Netherlands | 6 | GS | ||||
| Total | 816 | 410 | 878 |
NCI National Cancer Institute, OUH Oslo University Hospital, UNIGE Università degli Studi di Genova, QIMR Queensland Institute of Medical Research, Sanger Wellcome Sanger Institute, KI Karolinska Institute, H. Bichat Hôpital Bichat-Claude Bernard, MGH Massachussets General Hospital, LUMC Leiden University Medical Center.
aSee Supplementary material for a complete list of the 22 contributing sites from the ten participant groups.